ScreenerHero

ANL Adlai Nortye Group Ltd.

NAS · US · Healthcare · Biotechnology · adlainortye.com
14.05USD-2.84%Mkt Cap: 904.79M $P/E: —

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap904.79M USD
Enterprise Value725.08M USD
Revenue (TTM)18.06M USD
Gross Profit18.06M USD
Net Income (TTM)-35.53M USD
Revenue/Share0.45 USD
Last Price14.05 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees109
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-49.14
PEG—
EV/EBITDA-33.49
EV/Revenue40.16
P/S51.57
P/B4.33
EPS (TTM)-0.66
EPS (Forward)-0.29
52W Range
0.879080% of range17.25
52W High17.25 USD
52W Low0.8790 USD
Profitability
Gross Margin100.00%
Oper. Margin-44.19%
EBITDA Margin-119.91%
Profit Margin-710.56%
ROE426.92%
ROA-103.18%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.45M USD
CapEx (TTM)187.00K USD
FCF Margin-63.41%
FCF Yield-1.27%
Net Debt-206.12M USD
Net Debt/EBITDA9.52
Balance Sheet
Debt/Equity-3.17
Current Ratio9.55
Quick Ratio9.24
Book Value/Sh3.34 USD
Cash/Share3.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)29.50 USD
Upside (mean)+110.0%
Target Range20.00 USD – 49.00 USD
20.00+110.0% to mean49.00
# Analysts6
Ownership
Shares Out.58.73M
Float49.57M
Insiders0.94%
Institutions41.33%
Short Interest
Short Ratio24.9d
Short % Float7.59%
Short % Out.6.87%
Shares Short4.42M
Short (prev mo.)4.30M
Technical
SMA 5014.33 (-2.0%)
SMA 20010.41 (+34.9%)
Beta1.11
S&P 52W Chg16.45%
Avg Vol (30d)159.17K
Avg Vol (10d)138.52K
Technical Indicators
RSI (14)42.6
MACD0.1781
MACD Signal0.4428
MACD Hist.-0.2647
BB Upper16.56 USD
BB Middle15.40 USD
BB Lower14.23 USD
BB Width15.17%
ATR (14)1.057 USD
Vol Ratio (20d)0.54x